Ets2 Regulates Colonic Stem Cells and Sensitivity to Tumorigenesis§


  • Jorge Múnera,

    1. Tumor Development Program, Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California, USA
    Search for more papers by this author
  • Grace Ceceña,

    1. Tumor Development Program, Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California, USA
    Search for more papers by this author
  • Paul Jedlicka,

    1. Department of Pathology, University of Colorado Denver, Aurora, Colorado
    Search for more papers by this author
  • Miriam Wankell,

    1. Tumor Development Program, Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California, USA
    Search for more papers by this author
  • Robert G. Oshima

    Corresponding author
    1. Tumor Development Program, Cancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California, USA
    • Tumor Development Program, Cancer Research Center, Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Rd, La Jolla, California 92037, USA
    Search for more papers by this author
    • Telephone: 858 646 3147; Fax: 858 646 3195

  • Disclosure of potential conflicts of interest is found at the end of this article.

  • Author contributions: J.M.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript composition; G.C.: collection and/or assembly of data; P.J.: data analysis; M.W.: collection and/or assembly of data; R.G.O.: conception and design, data analysis and interpretation, manuscript composition.

  • §

    First published online in STEM CELLSEXPRESS January 14, 2011.


Ets2 has both tumor repressive and supportive functions for different types of cancer. We have investigated the role of Ets2 within intestinal epithelial cells in postnatal mouse colon development and tumorigenesis. Conditional inactivation of Ets2 within intestinal epithelial cells results in over representation of Ets2-deficient colon crypts within young and adult animals. This preferential representation is associated with an increased number of proliferative cells within the stem cell region and an increased rate of crypt fission in young mice that result in larger patches of Ets2-deficient crypts. These effects are consistent with a selective advantage of Ets2-deficient intestinal stem cells in colonizing colonic crypts and driving crypt fission. Ets2-deficient colon crypts have an increased mucosal thickness, an increased number of goblet cells, and an increased density. Mice with Ets2-deficient intestinal cells develop more colon tumors in response to treatment with azoxymethane and dextran sulfate sodium. The selective population of colon crypts, the altered differentiation state and increased sensitivity to carcinogen-induced tumors all indicate that Ets2 deficiency alters colon stem cell number or behavior. Ets2-dependent, epithelial cell-autonomous repression of intestinal tumors may contribute to protection from colon cancer of persons with increased dosage of chromosome 21. STEM CELLS 2011;430–439


Colorectal cancer is one of the leading causes of cancer-related death in the U.S. Approximately 150,000 cases and 50,000 deaths due to the disease occurred last year. Alterations in the Wnt signaling pathway are common causes of colorectal adenoma formation. Ets2, a member of the Ets family of transcription factors, is located on human chromosome 21 and has been identified as a Wnt target in colorectal cancer cells and intestinal stem cells [1]. Ets2 is expressed within intestinal crypts in both mice and humans [2] and may be both a direct Wnt pathway target, as revealed by T-cell factor binding sites in the Ets2 promoter and indirectly regulated by the Achaete Scute-like 2 transcription factor (Ascl2), a direct Wnt target in intestinal stem cells [3].

Ets2 is reported to contribute to the repression of adenomatous polyposis coli multiple intestinal neoplasia (APCmin)-induced intestinal tumor formation in a mouse model of human trisomy 21 [4]. The smallest interval of trisomy that resulted in decreased intestinal tumors arising in mice carrying a mutation of the Apc tumor suppressor gene (Apcmin/+) included Ets2 among 30 candidate genes. Combining a targeted Ets2 allele with the additional chromosomal intervals revealed an Ets2 copy number-dependent suppression of intestinal tumors. The authors suggested that the Ets2 tumor repressive activity might be active against multiple types of tumors and thus support the hypothesis that trisomy 21 may confer broad resistance to cancer. However, another recent study using the Tc1 transchromosomic mouse model of Down's syndrome found that human genes located on Hsa21 but not including Ets2, restricted transplanted tumor growth by limiting angiogenesis [5]. In contrast to a tumor-repressive effect, we have previously shown that Ets2 has a stromal, supportive function on multiple transgenic mouse mammary tumor models [6–8].

Stem cells appear to be the cell of origin of colorectal cancer based on their existence throughout the lifetime of an individual and thus their capacity to acquire the multiple genetic mutations, which lead to colorectal cancer. Direct evidence for intestinal stem cells as the source of intestinal tumors came from a study of tissue-specific expression of Cre recombinases to inactivate a conditional Apc allele [9]. Whereas deletion of Apc in nonstem cells resulted in adenomas at very low frequency and with long latency, inactivation of Apc within stem cells led to formation of macroscopic adenomas within 36 days. Furthermore, these adenomas retained a small percentage of cells which expressed the intestinal stem cell marker Lgr5. These data support the view that intestinal stem cells are the target of the origin of intestinal cancer. Alteration of intestinal stem cell number or proliferation state may increase the probability of intestinal tumorigenesis.

Here, we have tested the epithelial cell-autonomous function of Ets2 during chemical carcinogenesis of the colon by using a conditional Ets2 allele and a transgene expressing Cre recombinase only in intestinal epithelial cells. We show that Ets2-deficient intestinal stem cells may have a selective advantage at colonizing colon crypts and an increased probability of colon tumor development when challenged by azoxymethane (AOM), a chemical carcinogen. We show that Ets2 has an epithelial cell autonomous, tumor-repressive activity for colon tumors. The protective effect of increased copies of the equivalent of Hsa21 is likely due to multiple genes including Ets2 but may be tumor type-dependent.



Generation of the Ets2A72 and Ets2flox alleles has been described previously [6, 10]. All mouse lines were introgressed into the FVB/N genetic background a minimum of six generations. Ets2flox was combined with the Villin-Cre (V-Cre) [11] and the R26R Cre reporter gene [12]. The R26R mice in a 129S3/SvImJ background were obtained from the Jackson Laboratory (Bar Harbor, Maine, and introgressed into the C57Bl6 genetic background. Mice were genotyped by polymerase chain reaction (PCR) as described previously [13]. For laser capture microdissection, 5-μm sections of colon stained for β-galactosidase and neutral red were dissected from colon tissue sections using MMICellCut tools and a CellCut Plus laser capture microdissection microscope (Molecular Machines and Industries, Haslett, Michigan, Captured tissue was digested with digestion buffer and used for PCR. For PCR of the Ets2db2 allele, the db2fwd1 (CCGTGTAGCAGAGAGAC AGG) and db2rev2 (GGGGGTCTCATACAGGACAG) primers were used at a concentration of 1 μM. For the Ets2flox allele the PshA1.a (GCCACAGCAAACCTCTTTCT) and PshA1.b (ACTTGTTGCAT GGGACACAC) primers were used at a concentration of 5 μm.

Tumor Induction and Analysis

For the colitis-associated cancer regimen [14, 15], 8-week-old mice were injected with 12.5 mg/kg of AOM. A week later, animals were subjected to 2.5% dextran sulfate sodium (DSS) in drinking water for 5 days followed by a 16-day recovery. The DSS cycle was repeated once more and then a final cycle of 2% DSS for 4 days with a recovery period of 10 days was done. Animals were sacrificed at the end of the regimen or after 10 additional weeks. Macroscopic tumors were observed under a dissection microscope, whereas microadenomas were counted from histological sections. Grading of adenomas was performed by two independent pathologists blinded to genotype.


Dissected colons were prepared as described [16] and fixed with either 4% formaldehyde in phosphate-buffered saline (PBS) or 2% paraformaldehyde and 0.2% glutaraldehyde in PBS for β-galactosidase staining. β-galactosidase staining was performed overnight with 1 mg/ml X-gal [17]. Fixed tissues was prepared as Swiss rolls, dehydrated, embedded, sectioned, and stained with H&E or with neutral red for X-gal-stained material by standard methods. Slides were scanned with a ×20 objective using an Aperio Scanscope XT slide scanner. Digital images of slides were examined using Aperio Imagescope software. Measurements of length were made using the pen and ruler tools. For quantitation of proliferating cell nuclear antigen (PCNA), F480 reaction and terminal apoptotic cells by the deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) method, tumor areas were defined using the ellipse tool and the area of positive reaction was measured using a threshold setting specific for each antibody.

Crypt Analysis

Crypts uniformly stained for β-galactosidase activity were judged at ×20 magnification on at least 80 well-oriented distal colon crypts per slide. To validate this method, slides were scored by an independent observer blinded to the genotype of the slide. The results from the independent observer for each individual slide were within 6% (on average) of the original measurements. Crypt fission was determined by measuring the number of crypts with bisecting fissure and a single luminal opening as previously described [18]. Patch size was measured on at least 100 well-oriented crypts per section. To determine crypt depth, the perpendicular distance from the submucosa surface to the luminal surface of individual crypts was measured at six different points along length of the colon. The frequency of goblet cells was measured as others have described [19]. Briefly, X-gal-stained colons were stained with periodic acid schiff reagent to visualize the mucin accumulations in goblet cells. Goblet cells were measured as a percentage of total cells within a crypt. Five different fields at ×200 magnification from four mice per genotype at 30 days of age were examined. For determining the total number of cells per crypt, 25–40 well-oriented crypts per genotype were measured as described [20]. For crypt density measurements, the lengths of at least three areas with 10 or more well-oriented crypts were measured using the pen tool in Imagescope.

Statistical Analysis

Data are presented as the mean ± SD unless otherwise specified. Student's t test was used to analyze differences between two groups. The one-way ANOVA test was used when more than two groups were compared. Mann-Whitney test was used when comparing two groups not displaying normal distribution.


Ets2-Deficient Intestinal Stem Cells Selectively Populate Colon Crypts

We combined a conditional-targeted allele of Ets2-designated Ets2flox [10], the 12.4-kb V-Cre recombinase transgene that is expressed throughout the intestinal epithelium [11] and the Rosa26 Cre reporter gene (R26R) that expresses β-galactosidase when activated by Cre recombinase [12]. V-Cre has been used in many studies that require the intestinal epithelial-specific expression of Cre recombinase from the crypt to the villus and from the duodenum through the colon. Expression of Cre leads to recombination of the Ets2flox allele to yield the Ets2db2 allele (Table 1). This deletion of the exons coding for the DNA binding domain inactivates the transcription factor and causes placental insufficiency in the whole animal [10]. We confirmed that expression of the Cre reporter gene was uniform in the epithelium of the small intestine (not shown) but was mosaically expressed in the colon [11]. Expression of the β-galactosidase reporter was greater in Ets2flox/flox, V-Cre, R26R mice than those mice with either Ets2+/+ or Ets2flox/+ in combination with V-Cre and R26R (Fig. 1A–1C). Enzymatic assays of β-galactosidase activity of colon tissue confirmed the histochemical pattern and demonstrated elevated expression of the reporter gene in animals homozygous for Ets2flox alleles in all portions of the colon with a proximal to distal gradient of decreasing reporter gene activity (Fig. 1D). Sections of the stained colons contained a larger number of uniformly stained crypts in mice homozygous for the Ets2 conditional allele (Fig. 2A, 2B). The expression of the R26R reporter gene is dependent on Cre activity and is expected to be concordant with recombination of the Ets2flox allele. As all crypt cells are derived within about 7 days from the differentiating progeny of stem cells located at the base of the crypt, the uniform staining of crypts reflects recombination in the stem cells of the crypt. In addition to being expressed within the stem cells, V-Cre is expressed in the differentiated cells of the crypt resulting in sporadic labeling of cells distal to the base. However, these cells are lost as the cells migrate to a luminal position and are then shed. To confirm that uniformly stained crypts represent fully recombined Ets2flox alleles, laser capture, microdissection of sections stained for β-galactosidase activity was performed followed by PCR analysis of the Ets2flox alleles. Figure 2C shows that uniformly blue crypts contained the Cre-mediated recombined Ets2db2 allele. By contrast, unstained crypts contained, nearly exclusively, the nonrecombined Ets2flox allele. Thus, the β-galactosidase reporter is a reliable indicator of the status of the Ets2 conditional allele. Intestinal stem cells populate the bottom of crypts that form by invagination during the first 2 weeks of postnatal life in the mouse [21]. To evaluate the apparent preferential colonization of crypts by Ets2-deficient stem cells, we examined mice of different ages. In the colon, extensive areas of blue crypts were found in Ets2flox/flox; V-Cre; R26R animals of ages 15, 30, 60, and 90 days (Fig. 2D). Ets2-deficient crypts were more abundant than controls at 15 days and increased rapidly during the next 2 weeks to represent about 70% of all crypts. The fraction of all blue crypts in control animals increased with age resulting in approximately 40% blue crypts by 90 days of age. These results suggest that Ets2-deficient stem cells have a selective advantage in competition with Ets2 competent stem cells resulting in a greater number of uniformly stained crypts.

Figure 1.

Increased representation of Ets2-deficient colons crypts. Representative whole mount images of distal colon areas stained for β-galactosidase. Examples are from areas 1 cm from the anus of 15-day female mice containing V-Cre, the R26R reporter gene and (A) Ets2+/+, (B) Ets2flox/+, and (C) Ets2flox/flox alleles. Note larger patches of blue-stained crypts in Ets2flox/flox genotype. (D): Ets2 dependence of β-galactosidase activity of the colon. The colons of 18-day-old mice were divided into four portions (proximal, mid-1, mid-2, and distal) homogenized and enzyme activity and protein content was determined. Two animals each of R26R, V-Cre mice with wt Ets2+/+ (open bars, 1–2); Ets2flox/+ (gray bars, 3–4); or Ets2 flox/flox (black bars, 5–6) were compared. Abbreviation: RLU, relative light units. [Color figure can be viewed in the online issue, which is available at]

Figure 2.

Ets2 dependence of uniformly populated crypts. (A): Representative sections of colon from Ets2 flox/flox, V-Cre, R26R and (B) Ets2flox/+, V-Cre, R26R mice stained for β-galactosidase (blue) and with neutral red. Black bars represent 100 μm. (C): Agarose gel analyses of PCR products of approximately 10 pooled individual crypt sections recovered by laser capture microdissection of β-galactosidase-positive and β-galactosidase-negative crypts from Ets2flox/flox, V-Cre, R26R mice. Mouse number from which the sections were obtained is indicated at the top. Ets2 genotype is indicated at right. Size markers are at left in bp. The “colon” sample represents whole tissue control. Ets2flox is recombined by Cre to generate the Ets2db2 allele in β-galactosidase-positive crypts. (D): Frequency of uniformly blue crypts was measured in sections of animals of different ages. The values represent the averages of at least 85 scored crypts from two sections of at least two mice of each genotype and age except for Ets2+/+ at 30 days and Ets2flox/+ at 90 days for which only one mouse was available. Two tailed Student's t test indicated the results for mice with the Ets2flox/flox genotype was significantly different from Ets2flox/+ or Ets2+/+. [Color figure can be viewed in the online issue, which is available at]

Table 1. Summary of gene combinations
inline image

Ets2-Deficient Crypts Divide More Rapidly

In the mouse, crypt fission increases the number of crypts during the second to third week after birth [22]. To evaluate the fission of Ets2-deficient crypts, we measured the number of bifurcating crypts at days 15 and 30. Figure 3A shows representative images of bifurcating crypts and a summary of measuring the number of dividing crypts. Crypts in division were much more numerous at day 15 than later, as expected from previous studies. Animals homozygous for the Ets2 conditional allele, in addition to the V-Cre and R26R genes, contained twice as many dividing crypts as animals heterozygous or wild type for Ets2 (Fig. 3D, age 15). This difference is apparent even though only about 40% of the crypts at this age were colonized by Ets2-deficient cells (Fig. 2). By 30 days of age, the number of dividing crypts greatly decreased and the number of bifurcating crypts was insufficient to distinguish the Ets2 genotypes. At 15 days the fraction of Ets2-deficient crypts in fission was found to be over 30%, whereas only about 10%–12% of similarly stained crypts from the Ets2 heterozygote or wild type were found to be dividing (Fig. 3E). If increased crypt fission is a cause of expansion of the Ets2-deficient monoclonal crypts, neighboring crypts should have the same genotype, and the patch size of crypts would be expected to be larger than control crypts. The patch size of Ets2-deficient crypts is larger than control mice heterozygous for Ets2flox for ages greater than 15 days (Fig. 1A, 3F). Thus, even though crypt fission greatly decreases after 15 days, the results of that increased rate of fission persists in the adult animals. These results are consistent with more rapidly dividing crypts at an early age, not just a larger number of Ets2-deficient crypts. Crypt fission is more frequent in colons of both Apcmin mice and human familial adenomatous polyposis samples [23].

Figure 3.

Crypt fission is increased in Ets2-deficient colons. Sections of V-Cre, R26R mice of varying Ets2 genotype and age stained for β-galactosidase were scored for bifurcating crypts. (A–C): Examples of crypts in fission for each genotype at postnatal day 15. (D): Frequency of dividing crypts as a function of age. For each measurement, at least 86 well-oriented crypts were scored. Error bars represent the standard deviation. The number of mice analyzed is the same as for Figure 2. (E): increased fission of Ets2-deficient crypts. Only blue crypts were scored at 15 and 30 days. (F): Crypt patch size increases with age in Ets2flox/flox but not in Ets2flox/+ mice. Patches of two or more adjacent crypts were measured. In Ets2flox/flox mice, patch sizes is greater after 15 days. Patch size of Ets2flox/+. Patch size differences within each genotype were measured using a one-way ANOVA test. For Ets2flox/flox mice, there was a significant difference in patch sizes within the group (p < .0001). Patch size in Ets2flox/+ mice was not significantly different with age as revealed by a one-way ANOVA test (p = .25). Differences in patch size between the two genotypes was determined by Mann-Whitney test (p < .0001). Abbreviation: ns, not significant. [Color figure can be viewed in the online issue, which is available at]

Ets2 Deficiency Results in Increased Proliferation at the Base of Colon Crypts

The selective advantage of Ets2-deficient intestinal stem cells could be due to increased mitotic activity of the stem cells, thus, providing a greater probability of out competing neighboring Ets2-competent stem cells. To measure the proliferation status of the cells of Ets2-deficient crypts, we identified cells actively synthesizing DNA by reaction with PCNA antibody and scored the location of the PCNA-positive cells along the entire depth of the crypt (Fig. 4). An increased number of PCNA-positive cells were located in the bottom third of crypts in mice with Ets2-deficient crypts. At age of 60–80 days, approximately 70% of the colon crypts of Ets2flox/flox, V-Cre mice are Ets2-deficient (Fig. 4). These results support the view that Ets2 deficiency alters the balance between self-renewal and differentiation resulting in more proliferative cells within the stem cell environment.

Figure 4.

Increased proliferation at the bottom of crypts from Ets2-deficient mice. (A): 3,3′ diaminobenzidine (DAB) reaction (brown) indicates reaction of nuclei with antibody to PCNA. The depth of individual crypts (vertical dotted line) was measured and used to divide the crypt into three parts (horizontal dotted lines). The arrow indicated PCNA-positive cells in the bottom of crypts from Ets2flox/flox V-Cre (f/f V-Cre+) mice that are not as common in (B) Ets2flox/flox mice without V-Cre (f/f V-Cre−). (C): Frequency of PCNA-positive cells in the bottom third of colon crypt. Error bar indicates the standard deviation. (D): The number of PCNA-positive cells in the middle third of colon crypts is not significantly different between the two genotypes. Abbreviations: ns, not significant; PCNA, proliferating cell nuclear antigen. [Color figure can be viewed in the online issue, which is available at]

If Ets2 deficiency causes an alteration in the self-renewal of intestinal stem cells, some difference in the differentiated state of colon crypts might be expected. Although the overall histological appearance of the intestines of animals with Ets2-deficient intestinal epithelial appear normal, the thickness of the colonic mucosa of mice with Ets2-deficient crypts was greater (supporting information Fig. S1A). This increased depth of the crypts accommodated an increased number of goblet cells/crypt (supporting information Fig. S1B) with no change in the total number of cells/crypt (supporting information Fig. S1C). In addition, Ets2-deficient crypts occur at a higher density than crypts which retain Ets2 (supporting information Fig. S1D). These results suggest that Ets2 deficiency may alter the balance of self-renewal and differentiation resulting in increased mitotic activity, increased number of goblet cells/crypt, and increased frequency of crypt fission. However, all of these differences appear to be tolerated within the normal functional requirements of the colon.

Ets2 Acts Within Intestinal Epithelial Cells to Repress Experimental Colon Adenoma Formation

If Ets2 restricts the self-renewal of colonic stem cells, a mitotically more active or larger number of intestinal stem cells might render Ets2-deficient intestinal epithelium more sensitive to neoplastic conversion. To determine if Ets2 may repress intestinal tumor formation in an epithelial cell autonomous way, we subjected Ets2flox/flox, V-Cre and control mice to AOM exposure and the dextran sodium sulfate-induced colitis regime that results in β-catenin-activating mutations and colon adenomas [14, 15]. Mice with Ets2-deficient crypts developed significantly more adenomas than control animals (Fig. 5B). Animals heterozygous for the conditional Ets2 allele had a tumor number that was nearly identical to Ets2flox/flox mice not expressing Cre. At an age of 60 days, when the mice were treated with AOM, about 70% of the colon crypts of Ets2flox/flox, V-Cre mice are monoclonal Ets2-deficient (Fig. 5B). We estimate that if all crypts of an animal were Ets2-deficient, the number of tumors per animal might be twice that of control animals (Fig. 5B). Although tumor number was influenced by Ets2 gene activity, tumor size and pathological state were not (supporting information Table S1). Furthermore, neither PCNA immunohistochemistry nor apoptotic cell index distinguished the tumor genotype. This is consistent with Ets2 influencing the initiation of colon tumor formation.

Figure 5.

Adenoma formation in mice treated with azoxymethane (AOM) and dextra sodium sulfate. Multiplicity but not size is increased in Ets2flox/flox, V-Cre mice compared with Ets2flox/+ V-Cre and Ets2flox/flox mice following the 9-week-AOM/dextran sulfate sodium (DSS) regimen. (A): Representative H&E-stained section of colon tumors from an Ets2flox/flox V-Cre. Scale bar = 500 μm. (B): Comparison of average number of tumors per mouse from AOM/DSS-treated mice of the Ets2flox/flox, V-Cre, Ets2flox/+, V-Cre, and Ets2flox/flox genotypes. The solid black column labeled db2/db2 represents the Ets2flox/flox, V-Cre group adjusted for the 30% of the crypts that do not express Cre at the age of AOM administration (Fig. 2). “n” represents number of mice examined. Results of Student's t test: *, p < .05; ***, p = .001. (C): Increased sensitivity of Ets2A72/A72 mice to AOM/DSS-induced tumors. Mice were examined 19 weeks after AOM/DSS administration. (D): Tumor number of individual mice. Each of the mice is ranked by the number of tumors found. (E): Schematic diagram of possible relationships of Ets2 and Wnt signaling pathway components. Ets2 may be both a direct target of β-catenin/TCF4 and downstream of Ascl2. Activation of Ets2 by Ras occurs through phosphorylation of Thr72 by Erk. P16 has been suggested to be a target of Ets2 in primary cells. Cdx2 is a direct target of Ets2 in trophoblast cells and is decreased in Ets2-deficient mouse colon. Abbreviations: AA, Ets2A72/A72; AOM, azoxymethane; APC, adenomatous polyposis coli; TCF4, T-cell factor 4; ns, not significant; WT, wild type. [Color figure can be viewed in the online issue, which is available at]

Increased Representation of Ets2-Deficient Tumor Cells

To evaluate the representation of Ets2-deficient tumor cells, PCR analysis of dissected tumors was performed. All 17 Ets2flox/flox, V-Cre tumors revealed both Ets2floxand Ets2db2 recombined alleles but none had exclusively Ets2flox/flox alleles (Table 2). As nonepithelial stromal cells are commonly found within these adenomas [24], we performed laser capture microdissection and PCR to evaluate the recombined status of the epithelial cells of Ets2flox/flox, V-Cre tumors. The epithelial cells of nine tumors contained only Ets2db2 alleles, whereas one contained a minor level of Ets2flox (Table 2). As approximately 30% of the crypts at the time of AOM treatment were Ets2flox/flox, a similar fraction of tumors would be expected if Ets2 inactivation was neutral. The over representation of Ets2-deficient epithelial cells within adenoma tumor cells, supports the view that Ets2 deficiency increases sensitivity to colon tumor initiation through an epithelial cell-autonomous cellular mechanism. In contrast to tumors from V-Cre mice homozygous for the Ets2flox allele, 5 of 17 tumors from V-Cre mice heterozygous for Ets2flox showed no signs of recombination. This was fewer than expected but more than tumors from Ets2flox/flox, V-Cre mice. This increased frequency of tumors with recombined Ets2flox alleles may reflect a modest increased sensitivity to tumor formation with modestly decreased Ets2 activity.

Table 2. Ets2 alleles within tumors
inline image

Ets2 Regulation by Mitogen-Activated Protein Kinase Contributes to Colon Tumor Repression

Ets2 is activated by phosphorylation of a single threonine in the evolutionarily conserved N-terminal-pointed domain that mediates docking and phosphorylation by Erk [25, 26]. We replaced Thr-72 with an alanine in the Ets2 gene to produce a hypomorphic allele (Ets2A72) in mice that permits survival in the homozygote state but is insufficient for placental function when combined with the knockout allele Ets2db1 [6]. To determine if activation of Ets2 through Thr-72 is important for its repressive activity on AOM-induced colon adenomas, we subjected Ets2A72/A72 females to the AOM/DSS tumor induction protocol. Seventy percentage of the Ets2A72/A72 (AA) animals developed tumors, whereas less than 30% of the control animals had tumors (Fig. 5C). The average tumor number was greater in the Ets2A72/A72 mice (Fig. 5D) although the average tumor size did not distinguish the two groups (data not shown). Histochemical analysis of PCNA, TUNEL, and F4/80 in tumors also did not distinguish the experimental groups (supporting information Fig. S2). Thus, activation of Ets2 through The-72 is important for the tumor repressive activity of Ets2 and most likely affects tumor initiation.


Ets2 has different functions in different cell types and tumors. Previously, we have shown that Ets2 supports mammary tumors through a stromal effect [6, 8] that was identified as fibroblasts [27]. However, in intestine an Ets2 copy number-dependent repression of Apcmin-induced tumors was found in the DS1 region of the mouse ortholog of human chromosome 21 [4]. Recently, a different region of Hsa21 that does not include Ets2 was implicated in inhibiting tumor angiogenesis of transplantable tumors in a second mouse model of Down's syndrome [5]. Our results indicate that Ets2 acts within intestinal epithelial cells to repress chemical carcinogen-induced colon tumors, and this activity is likely associated with restricting intestinal stem cells. Thus, Ets2 may be additive with other mouse orthologs and human genes located on Hsa21 to repress tumors. However, this Ets2 contribution may be specific to intestinal tumors driven by the Wnt pathway. Thus, multiple genes of Hsa21 may contribute to resistance to cancer via different tumor-specific mechanisms. A role for Ets2 within intestinal stem cells was anticipated from the identification of Ets2 as a target of the Wnt pathway [1, 28] and its regulation by Ascl2 in intestinal stem cells [3]. However, in contrast to the conditional inactivation of Wnt targets Ascl2 and Myc, inactivation of Ets2 within the intestinal epithelium leads to increased crypt cell proliferation and increased tumor sensitivity [3, 29] rather than the loss of Myc- or Ascl2-deficient crypts. Ets2 acts to moderate the proliferation response of the Wnt pathway within the intestine such as Lgr5, a stem cell marker and Wnt target [30]. The potential interaction of Ets2 within the Wnt pathway in altering colon stem cell fate is shown in Figure 5E.

We deduce that Ets2 regulates colonic stem cell self-renewal because of the over representation of uniformly Ets2-deficient crypts. Competition between intestinal stem cells results in monoclonal crypt conversion, even between equally competitive cells [31–33]. The identification of crypts of Ets2+/+, V-Cre and Ets2flox/+, V-Cre that uniformly express the R26R reporter gene are examples of normal monoclonal conversion [34, 35]. The competitive advantage of Ets2-deficient stem cells may be reflected by the increased number or activity of proliferative cells at the bottoms of colon crypts. Although the epithelium autonomous function of Ets2 revealed by Villin-Cre might be elicited through cells adjacent to the stem cells [33], the over representation of Ets2-deficient tumor cells within tumors suggests a tumor cell-autonomous function. Direct proof of a stem cell autonomous function must necessarily await quantitation of isolated colonic stem cells in the presence and absence of active Ets2.

Stem cell colonization and crypt fission appear closely related. However, the regulation of crypt fission has not been studied extensively. APC mutations that drive adenoma formation from a stem cell, results in increased crypt fission perhaps even in the absence of increased epithelial cell proliferation [23]. The re-emergence of intestinal crypts that express Myc or Ascl2 after the conditional inactivation of either gene reveals a connection between competitive advantage of stem cells and increased crypt fission [3, 29]. Fission has been implicated as a mechanism for spread of mutations in the intestine of both mice and humans [36, 37]. To date, alterations in genes that affect intestinal stem cells (APC, Myc, Ascl2), also affect crypt fission. The possible expansion of Ets2-deficient stem cells within individual crypts and by crypt fission may result in an expanded population of colonic stem cells. One consequence of a larger population of Ets2-deficient colonic stem cells number would be an expected increase in AOM-induced tumor sensitivity because the intestinal stem cells are the cell of origin of intestinal tumorigenesis in mice [9]. This prediction was supported by the AOM/DSS experiments with Ets2flox/flox, V-Cre, and the Ets2A72/A72 animals.

The activation of Ets2 through the phosphorylation of threonine 72 is important for its tumor-repressive activity. This may reflect the dual roles of Ras/Erk activation in senescence of normal cells and its oncogenic role in cancer. For intestinal stem cells, Ets2 may integrate the increased activity of the Wnt pathway and growth factor signaling normally associated with mitotic activity. Ets2 contributes to the regulation of multiple genes that may influence intestinal stem cell self-renewal or differentiation. Cdx2 expression is decreased within the colons of Ets2-deficient mice rescued from placental insufficiency [10]. Cdx2 regulates early intestinal morphogenesis and early embryonic axis development [38] and suppresses tumorigenesis in the distal colon in response to AOM injections [39]. Matrix metalloprotease-9 (MMP-9) expression is decreased in some but not all expressing tissues of Ets2-deficient mice [13] and is important for differentiation toward the absorptive lineage. MMP-9 deficiency may lead to Notch1 inhibition and subsequent accumulation of goblet cells [40]. MMP-9 also acts as a tumor suppressor in colitis-associated cancer [41]. Finally, Ets2 has been suggested to be important in restricting the self-renewal of primary fibroblasts by regulating p16 [42]. Ets2 regulation of p16 may be restricted by degradation of Ets2 by the Cdh1 component of the anaphase promoting complex during the cell cycle [43]. Confirmation of involvement of any or all of these Ets2 targets will be most definitively evaluated in isolated Ets2-deficient colonic stem cells.

In summary, our results indicate that while Ets2 is a Wnt pathway target gene within intestinal stem cells, its loss provides a competitive advantage for intestinal stem cells to colonize crypts, increase basal crypt cell proliferation, and increases crypt fission. Ets2 loss may increase the number or sensitivity of colon stem cells for tumor initiation.


We thank Robbin Newlin of the Histology Resource and Katina Candee, Michael Florio, and Adriana Charbono of the Animal Resource for expert technical assistance. We thank Deborah Gumucio, University of Michigan Medical School and Frank Gonzales, NIH for the Villin-Cre mice. This work was supported by grants from the NIDDK and NCI (RO1 DK092084, P01 CA102583) and a pilot grant from the Cancer Center Support grant P30 CA30199. J.M. was supported by a research supplement to promote diversity in health-related research P01-CA102583-05S1.


The authors indicate no potential conflicts of interest.